TXNIP and diabetes mellitus: Several preclinical and clinical evidence related to diabetes mellitus supported the TXNIP-specific inhibitors for the development of new promising agents (Qayyum et al., 2021), such as Verapamil (Khodneva et al., 2016), Taurine (Gondo et al., 2012), and SRI-37330 (Thielen et al., 2020).